Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain

A randomized, double-blind, parallel-group study

Patricia Mucci-LoRusso, Barry S. Berman, Peter T. Silberstein, Marc L. Citron, Linda Bressler, Sharon M. Weinstein, Robert F. Kaiko, Barbara J. Buckley, Robert F. Reder

Research output: Contribution to journalArticle

156 Citations (Scopus)

Abstract

Controlled-release oral formulations of oxycodone and morphine are both suitable analgesics for moderate to severe pain. They were compared in cancer-pain patients randomized to double-blind treatment with controlled- release oxycodone (n = 48) or controlled-release morphine (n = 52) every 12 h for up to 12 days. Stable analgesia was achieved by 83% of controlled- release oxycodone and 81% of controlled-release morphine patients in 2 days (median). Following titration to stable analgesia, pain intensity (0=none to 3 =severe) decreased from baseline within each group (p ≤ 0.005), from 1.9 (0.1) to 1.3 (0.1), mean (SE), with controlled-release oxycodone, and from 1.6 (0.1) to 1.0 (0.1) with controlled-release morphine (no significant between-group differences). Typical opioid adverse experiences were reported in both groups. Hallucinations were reported only with controlled-release morphine (n=2). Visual analog scores (VAS) for 'itchy' and 'scratching' were lower with controlled-release oxycodone (p ≤ 0.044), as was peak-to-trough fluctuation in steady-state plasma concentration (p=0.004). The correlation between plasma concentration and dose was stronger (p=0.026) for oxycodone (0.7) than morphine (0.3). The relationship between pain intensity (VAS) and plasma concentration was more positive for oxycodone (p=0.046). There was a positive relationship between morphine-6-glucuronide concentrations and urea nitrogen and creatinine levels (p=0.0001). Controlled-release oxycodone was as effective as controlled-release morphine in relieving chronic cancer- related pain, and as easily titrated to the individual's need for pain control. While adverse experiences were similar, controlled-release oxycodone was associated with less itching and no hallucinations. Controlled-release oxycodone provides a rational alternative to controlled-release morphine for the management of moderate to severe cancer-related pain.

Original languageEnglish
Pages (from-to)239-249
Number of pages11
JournalEuropean Journal of Pain
Volume2
Issue number3
DOIs
StatePublished - 1998

Fingerprint

Oxycodone
Morphine
Therapeutics
Pain
Hallucinations
Analgesia
Cancer Pain
Pruritus
Chronic Pain
Opioid Analgesics
Analgesics
Urea
Creatinine
Nitrogen

All Science Journal Classification (ASJC) codes

  • Anesthesiology and Pain Medicine
  • Neurology
  • Neuropsychology and Physiological Psychology

Cite this

Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain : A randomized, double-blind, parallel-group study. / Mucci-LoRusso, Patricia; Berman, Barry S.; Silberstein, Peter T.; Citron, Marc L.; Bressler, Linda; Weinstein, Sharon M.; Kaiko, Robert F.; Buckley, Barbara J.; Reder, Robert F.

In: European Journal of Pain, Vol. 2, No. 3, 1998, p. 239-249.

Research output: Contribution to journalArticle

Mucci-LoRusso, Patricia ; Berman, Barry S. ; Silberstein, Peter T. ; Citron, Marc L. ; Bressler, Linda ; Weinstein, Sharon M. ; Kaiko, Robert F. ; Buckley, Barbara J. ; Reder, Robert F. / Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain : A randomized, double-blind, parallel-group study. In: European Journal of Pain. 1998 ; Vol. 2, No. 3. pp. 239-249.
@article{886fc052751b4732aa42b675ad2546c2,
title = "Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: A randomized, double-blind, parallel-group study",
abstract = "Controlled-release oral formulations of oxycodone and morphine are both suitable analgesics for moderate to severe pain. They were compared in cancer-pain patients randomized to double-blind treatment with controlled- release oxycodone (n = 48) or controlled-release morphine (n = 52) every 12 h for up to 12 days. Stable analgesia was achieved by 83{\%} of controlled- release oxycodone and 81{\%} of controlled-release morphine patients in 2 days (median). Following titration to stable analgesia, pain intensity (0=none to 3 =severe) decreased from baseline within each group (p ≤ 0.005), from 1.9 (0.1) to 1.3 (0.1), mean (SE), with controlled-release oxycodone, and from 1.6 (0.1) to 1.0 (0.1) with controlled-release morphine (no significant between-group differences). Typical opioid adverse experiences were reported in both groups. Hallucinations were reported only with controlled-release morphine (n=2). Visual analog scores (VAS) for 'itchy' and 'scratching' were lower with controlled-release oxycodone (p ≤ 0.044), as was peak-to-trough fluctuation in steady-state plasma concentration (p=0.004). The correlation between plasma concentration and dose was stronger (p=0.026) for oxycodone (0.7) than morphine (0.3). The relationship between pain intensity (VAS) and plasma concentration was more positive for oxycodone (p=0.046). There was a positive relationship between morphine-6-glucuronide concentrations and urea nitrogen and creatinine levels (p=0.0001). Controlled-release oxycodone was as effective as controlled-release morphine in relieving chronic cancer- related pain, and as easily titrated to the individual's need for pain control. While adverse experiences were similar, controlled-release oxycodone was associated with less itching and no hallucinations. Controlled-release oxycodone provides a rational alternative to controlled-release morphine for the management of moderate to severe cancer-related pain.",
author = "Patricia Mucci-LoRusso and Berman, {Barry S.} and Silberstein, {Peter T.} and Citron, {Marc L.} and Linda Bressler and Weinstein, {Sharon M.} and Kaiko, {Robert F.} and Buckley, {Barbara J.} and Reder, {Robert F.}",
year = "1998",
doi = "10.1016/S1090-3801(98)90020-9",
language = "English",
volume = "2",
pages = "239--249",
journal = "European Journal of Pain",
issn = "1090-3801",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain

T2 - A randomized, double-blind, parallel-group study

AU - Mucci-LoRusso, Patricia

AU - Berman, Barry S.

AU - Silberstein, Peter T.

AU - Citron, Marc L.

AU - Bressler, Linda

AU - Weinstein, Sharon M.

AU - Kaiko, Robert F.

AU - Buckley, Barbara J.

AU - Reder, Robert F.

PY - 1998

Y1 - 1998

N2 - Controlled-release oral formulations of oxycodone and morphine are both suitable analgesics for moderate to severe pain. They were compared in cancer-pain patients randomized to double-blind treatment with controlled- release oxycodone (n = 48) or controlled-release morphine (n = 52) every 12 h for up to 12 days. Stable analgesia was achieved by 83% of controlled- release oxycodone and 81% of controlled-release morphine patients in 2 days (median). Following titration to stable analgesia, pain intensity (0=none to 3 =severe) decreased from baseline within each group (p ≤ 0.005), from 1.9 (0.1) to 1.3 (0.1), mean (SE), with controlled-release oxycodone, and from 1.6 (0.1) to 1.0 (0.1) with controlled-release morphine (no significant between-group differences). Typical opioid adverse experiences were reported in both groups. Hallucinations were reported only with controlled-release morphine (n=2). Visual analog scores (VAS) for 'itchy' and 'scratching' were lower with controlled-release oxycodone (p ≤ 0.044), as was peak-to-trough fluctuation in steady-state plasma concentration (p=0.004). The correlation between plasma concentration and dose was stronger (p=0.026) for oxycodone (0.7) than morphine (0.3). The relationship between pain intensity (VAS) and plasma concentration was more positive for oxycodone (p=0.046). There was a positive relationship between morphine-6-glucuronide concentrations and urea nitrogen and creatinine levels (p=0.0001). Controlled-release oxycodone was as effective as controlled-release morphine in relieving chronic cancer- related pain, and as easily titrated to the individual's need for pain control. While adverse experiences were similar, controlled-release oxycodone was associated with less itching and no hallucinations. Controlled-release oxycodone provides a rational alternative to controlled-release morphine for the management of moderate to severe cancer-related pain.

AB - Controlled-release oral formulations of oxycodone and morphine are both suitable analgesics for moderate to severe pain. They were compared in cancer-pain patients randomized to double-blind treatment with controlled- release oxycodone (n = 48) or controlled-release morphine (n = 52) every 12 h for up to 12 days. Stable analgesia was achieved by 83% of controlled- release oxycodone and 81% of controlled-release morphine patients in 2 days (median). Following titration to stable analgesia, pain intensity (0=none to 3 =severe) decreased from baseline within each group (p ≤ 0.005), from 1.9 (0.1) to 1.3 (0.1), mean (SE), with controlled-release oxycodone, and from 1.6 (0.1) to 1.0 (0.1) with controlled-release morphine (no significant between-group differences). Typical opioid adverse experiences were reported in both groups. Hallucinations were reported only with controlled-release morphine (n=2). Visual analog scores (VAS) for 'itchy' and 'scratching' were lower with controlled-release oxycodone (p ≤ 0.044), as was peak-to-trough fluctuation in steady-state plasma concentration (p=0.004). The correlation between plasma concentration and dose was stronger (p=0.026) for oxycodone (0.7) than morphine (0.3). The relationship between pain intensity (VAS) and plasma concentration was more positive for oxycodone (p=0.046). There was a positive relationship between morphine-6-glucuronide concentrations and urea nitrogen and creatinine levels (p=0.0001). Controlled-release oxycodone was as effective as controlled-release morphine in relieving chronic cancer- related pain, and as easily titrated to the individual's need for pain control. While adverse experiences were similar, controlled-release oxycodone was associated with less itching and no hallucinations. Controlled-release oxycodone provides a rational alternative to controlled-release morphine for the management of moderate to severe cancer-related pain.

UR - http://www.scopus.com/inward/record.url?scp=0031718458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031718458&partnerID=8YFLogxK

U2 - 10.1016/S1090-3801(98)90020-9

DO - 10.1016/S1090-3801(98)90020-9

M3 - Article

VL - 2

SP - 239

EP - 249

JO - European Journal of Pain

JF - European Journal of Pain

SN - 1090-3801

IS - 3

ER -